Pique

Pique Therapeutics was a clinical-stage biotechnology company focused on developing personalized, "off-the-shelf" immunotherapies for the treatment of cancer. The company's lead candidate, PTX-9908, was an allogeneic whole-cell therapeutic vaccine designed to stimulate the immune system against multiple tumor-associated antigens in non-small cell lung cancer (NSCLC). PTX-9908 demonstrated promising results in Phase 2 clinical trials, showing a significant survival benefit in patients with advanced disease. Despite its clinical progress, the company has become inactive in recent years, with no recent updates on its development pipeline or corporate operations.